The current study was designed to evaluate the toxicity of mirazid. The drug was administered orally to male albino rats daily for five successive days, at a dose of 500 mg/kg body weight. The in vivo study showed no mortality or relevant changes in hematology or clinical biochemistry in mirazid-treated rats. However, there were notable signs of loss of appetite and gastrointestinal distress; besides, the decrease in body and relative weights of all organs. The stomach of treated rats was atrophied with severe muscular hypercontraction. On the other hand, the in vitro study showed that mirazid had no cytotoxic effect on Vero cell line, and had negligible antioxidant and antimicrobial activities. Taken together, mirazid failed to show beneficial effects. Since consistency in composition and biological action are essential requirements for an effective drug, one could say that mirazid is not a promising drug and share nothing with myrrh, except its bitterness.